John Paulson Buys 1,029,098 Shares of Bausch Health Companies Inc. (NYSE:BHC) Stock

Bausch Health Companies Inc. (NYSE:BHC) Director John Paulson acquired 1,029,098 shares of Bausch Health Companies stock in a transaction that occurred on Wednesday, June 11th. The shares were purchased at an average price of $5.24 per share, for a total transaction of $5,392,473.52. Following the transaction, the director now directly owns 28,222,267 shares in the company, valued at $147,884,679.08. The trade was a 3.78% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink.

John Paulson also recently made the following trade(s):

• On Thursday, June 12th, John Paulson purchased 1,005,376 shares of Bausch Health Companies stock. The shares were purchased at an average cost of $5.47 per share, for a total transaction of $5,499,406.72.
• On Tuesday, June 10th, John Paulson purchased 754,134 shares of Bausch Health Companies stock. The shares were purchased at an average price of $5.05 per share, for a total transaction of $3,808,376.70.

Bausch Health Companies Price Performance

Shares of BHC opened at $6.02 on Friday. The business has a 50-day moving average of $4.85 and a 200-day moving average of $6.43. The company has a market capitalization of $2.23 billion, a price-to-earnings ratio of -50.12, a price-to-earnings-growth ratio of 0.37 and a beta of 0.28. Bausch Health Companies Inc. has a 1 year low of $3.96 and a 1 year high of $9.85.

Analyst Ratings Changes

Several equities research analysts recently commented on BHC shares. Royal Bank of Canada lifted their target price on shares of Bausch Health Companies from $8.50 to $10.00 and gave the stock a “sector perform” rating in a research report on Friday, May 2nd. Wall Street Zen downgraded shares of Bausch Health Companies from a “buy” rating to a “hold” rating in a research note on Saturday, May 10th. One equities research analyst has rated the stock with a sell rating and seven have issued a hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $7.42.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in BHC. JPMorgan Chase & Co. boosted its stake in shares of Bausch Health Companies by 1,246.0% in the 4th quarter. JPMorgan Chase & Co. now owns 19,840 shares of the company’s stock valued at $160,000 after purchasing an additional 18,366 shares during the last quarter. Vanguard Group Inc. boosted its position in Bausch Health Companies by 1.3% during the fourth quarter. Vanguard Group Inc. now owns 11,684,859 shares of the company’s stock valued at $94,460,000 after acquiring an additional 145,078 shares during the last quarter. Raymond James Financial Inc. acquired a new stake in Bausch Health Companies during the 4th quarter worth about $180,000. Two Sigma Investments LP raised its position in shares of Bausch Health Companies by 688.2% in the 4th quarter. Two Sigma Investments LP now owns 265,461 shares of the company’s stock worth $2,140,000 after acquiring an additional 231,781 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its stake in shares of Bausch Health Companies by 1.1% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,284,036 shares of the company’s stock valued at $10,375,000 after purchasing an additional 14,558 shares during the period. Institutional investors own 78.65% of the company’s stock.

Bausch Health Companies Company Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.